comprehensive -WSS

comprehensive

author：leisure time 2025-09-14 08:23:07 - browse：6

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Popular nasal decongestant doesn't actually relieve congestion

Wikipedia

WSS

Telehealth for opioid use disorder is lifesaving

Long Covid needs a new name — and a new frame

Telehealth for opioid use disorder is lifesaving

Private equity could exacerbate cardiology's overuse problem, experts fear

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

White House touts steps to stem shortages of cancer treatments

focus

comprehensive

leisure time

Medical records are filled with copy

Acelyrin, a rare IPO success, stumbles in its first big test

In age of alternative facts, a scholarly course on calling out crap

FDA proposes changes to key medical devices approval pathway

Medical leaders decry Supreme Court decision on affirmative action

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Malaria cases in Florida and Texas: Here’s what you need to know

First Opinion Podcast: How to protect health care in times of war

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Food makers to regulators: Ultra

hotspot

Medtronic CEO on promising devices for diabetes, hypertension

Cassava reveals details — and problems — with Alzheimer's study

Maker of FluMist seeks to allow at

FDA proposes changes to key medical devices approval pathway

New Covid vaccine is recommended for everyone 6 months or older

Will the IRA bring competition to the biologics market?

Wikipedia

hotspot

leisure time

entertainment